Seasonal influenza vaccination and antiviral use in EU/EEA Member States
Seasonal influenza vaccination and antiviral use in EU/EEA Member States
English (1.84 MB - PDF)Read more on this site
None of the European Union (EU) Member States could demonstrate that they reach the EU target of 75% influenza vaccination coverage for vulnerable groups, according to a new report from the European Centre for Disease Prevention and Control (ECDC).
ECDC is collecting, sharing and disseminating information on national vaccination programmes and provides guidance for improving the overall performance of the vaccination systems in EU/EEA Member States. The latest data on vaccination coverage by country in the EU/EEA of different risk- and target groups are available in the reports listed on this page.
General disease information for public health experts and the general public on seasonal influenza.
More about this topic
Guidelines, information and data on vaccination for seasonal influenza.
There are several possible immunisation strategies for seasonal influenza.
Some people are at high risk of serious complications as a result of influenza, some of which can be life-threatening and result in death.
Injected trivalent inactivated influenza vaccines are most commonly used throughout the world. Influenza antigen preparation varies between manufacturers.
Information on natural immunity and immunity after vaccination, and the evaluation of immune response after vaccination in the EU.
It takes 10 to 14 days following vaccination, before an immune response and protection develops. Therefore, most countries start immunisation in the early autumn.
All updates on seasonal influenza
Share this page